Background and objective: The St George's Respiratory Questionnaire (SGRQ) is a self-administered questionnaire used to assess health-related quality of life (HRQoL) in various chronic respiratory diseases. Few studies have assessed the performance of the SGRQ in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). We aimed to examine the SGRQ's performance characteristics and generate data to support its reliability and validity in patients with CTD-ILD. Methods: We used data from 193 CTD-ILD patients evaluated at Tosei General Hospital from May 2007 to July 2016 to assess the cross-sectional and longitudinal validity of the SGRQ. Results: The mean age of the patients was 64.2 years and 122 (63.2%) were women. There were no significant differences in SGRQ scores between any of the CTD groups. Internal consistency (Cronbach's α = 0.905) and repeatability (intraclass correlation coefficient (ICC) = 0.873) for the SGRQ total score were excellent. At baseline, SGRQ total score was significantly associated with clinically meaningful measures of physiological function, exercise capacity and dyspnoea. Change in SGRQ total score over 6 months was also associated with change in other measures. Cox proportional hazards models showed that higher baseline SGRQ total score was a significant predictor of mortality. The estimated minimal clinically important difference of SGRQ total score was 4-13 points. Conclusion: These data support the validity and reliability of SGRQ as a sensitive measure for capturing HRQoL in patients with CTD-ILD.
INTRODUCTION
Interstitial lung disease (ILD) is a common pulmonary manifestation associated with connective tissue disease (CTD), resulting in significant morbidity and mortality. [1] [2] [3] [4] [5] [6] [7] Patients with CTD-ILD often experience impaired health -related quality of life (HRQoL). [8] [9] [10] The St George's Respiratory Questionnaire (SGRQ) was originally developed for patients with chronic obstructive pulmonary disease (COPD), and it has become one of the most extensively used tools for assessing HRQoL in patients with chronic respiratory diseases, including lymphangioleiomyomatosis, cystic fibrosis and idiopathic pulmonary fibrosis (IPF). [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Few studies have assessed the performance of the SGRQ in patients with CTD-ILD. 22, 23 The aim of this study was to extend knowledge on the SGRQ by examining its reliability and validity in patients with CTD-ILD.
METHODS

Study subjects and setting
We used data from CTD-ILD patients evaluated at Tosei General Hospital from May 2007 to July 2016, and conducted studies aimed at assessing the crosssectional and longitudinal validity of the SGRQ. CTD-ILD patients who underwent a systematic evaluation that included pulmonary function tests, responding to standardized questionnaires and performing an assessment of exercise capacity were eligible for enrolment. CTD was diagnosed when patients fulfilled the established, published criteria for rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), Sjogren's syndrome (SjS), systemic lupus erythematosus (SLE) or mixed CTD (MCTD). [24] [25] [26] [27] [28] [29] Clinically amyopathic DM (CADM) was diagnosed when a patient had a skin rash characteristic of DM without clinical evidence of muscle disease and with little or no increase in the serum creatinine kinase level. 30, 31 The diagnosis of ILD was based on expert evaluation and Data are presented as number (%) or mean (SD). † SLE, n = 4; MCTD, n = 6; RA + SSc, n = 1; RA + SjS, n = 2; PM + SSc + SjS, n = 1; PM + SjS, n = 1; DM + SjS, n = 1; SSc + SjS + SLE, n = 1; SSc + SjS, n = 2; MCTD + SjS + SLE, n = 1; MCTD + SjS, n = 1.
‡ RA, n = 67; SSc, n = 38; PM/DM, n = 36; SjS, n = 24; others, n = 19. § RA, n = 56; PM/DM, n = 36; SjS, n = 25; others, n = 20. ¶ RA, n = 65; SSc, n = 38; PM/DM, n = 34; others, n = 19. 6MWD, 6-min walk distance; CTD, connective tissue disease; CTD-ILD, CTD-associated ILD; DL CO , diffusing capacity of the lung for carbon monoxide; DM, dermatomyositis; FEV 1 
Measurements
Pulmonary function tests and arterial blood gas test
Spirometry (CHESTAC-55V, Chest M.I., Inc., Tokyo, Japan) and the diffusing capacity of the lung for carbon monoxide (DL CO ; CHESTAC-55V, Chest M.I., Inc.) were measured according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) recommendations. 32, 33 The values for forced vital capacity (FVC) and DL CO are reported as the percentage of predicted values based on age, gender and height. The gender, age and physiology variables (GAP) score was calculated from data obtained at initial evaluation. 34 Arterial blood gases were measured at rest.
Questionnaire tests
The SGRQ is a self-administered questionnaire for assessing HRQoL in respiratory diseases, which was previously validated. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] It contains three domains, all scored from 0 to 100. The symptom scale assesses respiratory symptom severity. The activity scale examines activity impairment due to respiratory symptoms. The impact scale evaluates the effects of respiratory symptoms on overall function and well-being. The total scale was calculated from all three components. Higher scores correspond to more impaired HRQoL. Permission for use of SGRQ scores was obtained from Dr Koichi Nishimura. Dyspnoea was assessed using the modified Medical Research Council dyspnoea scale (mMRC), which is a 5-point scale that asks respondents to rate dyspnoea from 0 (absent) to 4 (dyspnoea). 18, 20, [34] [35] [36] [37] Exercise capacity
Functional sub-maximal exercise capacity was evaluated using the 6-min walk test (6MWT) as described in the ATS statement. 38 Patients were instructed to walk as far as possible in 6 min, and the distance they could walk was recorded. Oxygen saturation (SpO 2 ) was also measured by pulse oximetry at rest for 5 min prior to and immediately after the test.
Statistical analysis
Continuous variables were expressed as mean AE SD. Categorical variables were summarized by frequency. The internal consistency of the SGRQ was assessed using Cronbach's α. Data from consecutive stable patients obtained on two occasions 3 months apart were investigated for repeatability using the intraclass correlation coefficient (ICC).
Correlation between two continuous variables was tested using Pearson's or Spearman's correlation coefficient. We considered the strength of correlations per convention: weak <0.30, moderate 0.30-0.60 and strong >0.60. 39 Construct validity was assessed by comparing mean SGRQ scores across subgroups of patients presumed to have different levels of ILD severity based on clinically meaningful measures, including % predicted FVC, % predicted DL CO , GAP score, partial pressure of oxygen (PaO 2 ), 6-min walk distance (6MWD), minimum SpO 2 (Min SpO 2 ) at 6MWT and mMRC, which served as anchors. Patients were stratified into quintiles based on anchor values and SGRQ scores were compared across quintiles using one-way analysis of variance (ANOVA) followed by pairwise comparisons with P-value adjustment according to the Tukey-Kramer method. Responsiveness was assessed using Pearson's or Spearman's correlation coefficients between changes in SGRQ scores and changes in anchors over 6 months. The relationship between mean change in SGRQ scores and changes in anchor (stratified into quintiles) was examined using analysis of covariance (ANCOVA), with baseline SGRQ score and change in anchor included as covariate, followed by Bonferroni post hoc tests.
The relationship between baseline SGRQ total score and mortality was evaluated using Cox proportional hazards models that included adjustment for age, gender and CTD type (RA vs non-RA, SSc vs non-SSc).
The minimal clinically important difference (MCID) of SGRQ total score was estimated using both distribution-and anchor-based methods. Distributionbased methods included the SEM. SEM was calculated for SGRQ total score by multiplying the estimated SD at baseline by the square root of one minus the estimated reliability coefficient. 40, 41 One SEM was defined to be the MCID. Because the SEM is sample-independent, corresponding estimates are considered bidirectional in nature. In the anchor-based analysis, we used linear regression to examine the relationship between change in SGRQ total score and change in the anchors (FVC, DL CO and mMRC). 42, 43 We derived a point estimate for the MCID by plugging into these equations values representing a minimal change (10% relative change in FVC, 15% change in DL CO and 1 point change in mMRC) in the independent variable. 42 Additionally, we calculated MCID estimates for improvement and those for decline according to median change in SGRQ total score for subjects who changed minimally according to FVC (10-15% relative change), DL CO (12-15% relative change) and mMRC (1 point) anchors.
All tests were performed at a significance level of P < 0.05. Analysis was completed using IBM SPSS statistics version 21 (IBM Corp. Armonk, NY, USA).
RESULTS
Baseline characteristics
During the period, 200 consecutive patients were diagnosed with CTD-ILD. Seven patients were excluded because questionnaires were not administered. The final cohort included 193 patients with CTD-ILD. The baseline characteristics of patients are summarized in Table 1 . Their mean age was 64.2 years and most were women. Most had RA. Pulmonary physiology revealed mild impairment in diffusing capacity. There were no significant differences in any score from the SGRQ between CTD groups (ANOVA, total, P = 0.172; symptom, P = 0.352; activity, P = 0.353; impact, P = 0.257, respectively).
Internal consistency and test-retest reliability
Cronbach's α for the SGRQ total and each dimension (symptom, activity and impact) were acceptable for a multidimensional instrument (α values = 0.905, 0.753, 0.894 and 0.851, respectively).
In the 44 stable patients, ICC for the SGRQ total and each domain (symptom, activity and impact) were 0.873, 0.836, 0.757 and 0.862, respectively. Table 2 shows the cross-sectional correlations between SGRQ scores and the anchors. In general, mean SGRQ total score and domain scores were greater for patients with lower FVC % predicted, DL CO % predicted, PaO 2 , 6MWD and nadir SpO 2 at 6MWT, and those with higher GAP score and mMRC value (Table 3) .
Construct validity
Responsiveness
Baseline and 6 months follow-up SGRQ scores were available for 117 patients. Of them, 61 patients (52%) were treated with immunosuppressive therapy within 6 months. Table 4 shows the longitudinal correlations between SGRQ scores and anchors. There were moderately strong correlations between 6-month change in SGRQ total score and 6-month change in FVC % predicted (relative change), DL CO % predicted (relative change), 6MWD, Min SpO 2 at 6MWT and mMRC. Mean improvements in SGRQ total scores mirrored improvements in anchors (Table 5) . Table 5 Mean changes in SGRQ scores by quintiles of changes in other measures over 6 months 
Survival analysis
During the observational period, 39 patients died. While adjusting for age, gender and CTD type, baseline SGRQ total score was significantly associated with mortality (Table  S1 , Supplementary Information).
Minimal clinically important difference
In the distribution-based analysis, MCID for SGRQ total score derived from the estimated SEM was 7 points (Table S2 , Supplementary Information). In the anchor-based analysis, mean MCID estimate for SGRQ total score derived from linear regression equations was 7 (5.4-8.8) points (Table S2 , Supplementary Information). Figure 1 shows the change in SGRQ total score over 6 months for each anchor. In general, there were trends for worsening in SGRQ total scores with deterioration of each anchor. In the second anchor-based analyses, mean MCID estimates for improvement and those for decline from the anchor criteria were −13 (−18.6 to −4.6) and 4 (1.8 to 6.6) points, respectively (Table S2 , Supplementary Information).
DISCUSSION
Although the SGRQ has been used to assess HRQoL in patients with various chronic respiratory diseases, this is the first study to evaluate its cross-sectional and longitudinal validity as a questionnaire capable of assessing HRQoL in patients with CTD-ILD. Our data suggest that SGRQ is a reliable and valid questionnaire for use in patients with CTD-ILD.
We found the SGRQ total and domain scores to possess adequate internal consistency in CTD-ILD, with alpha values greater than the widely accepted threshold of 0.7. In previously published studies, the SGRQ was found to have similarly acceptable internal consistency in cohort with IPF or SSc-ILD. 19, 22 Furthermore, test-retest reliability of SGRQ total score in patients with stable disease was acceptable (ICC = 0.873), exceeding the widely accepted cut-off value for utility of 0.8.
Significant correlations between SGRQ scores and clinically relevant anchors support its construct validity. Mean SGRQ scores were generally greater for patients with more severe disease as defined by values for pulmonary physiology, gas exchange and dyspnoea. In previously published studies, similar patterns were found in cohort of patients with IPF or SSc-ILD. 18, 19, 22 Our results extend those findings to a heterogeneous population of patients with various CTD.
We also observed significant associations between 6-month change scores for the SGRQ and 6-month change in values for our selected anchors, findings that further support the validity and responsiveness of the SGRQ in patients with CTD-ILD.
In a survival analysis, while adjusting for potentially influential confounders, higher baseline SGRQ total score (i.e. worse HRQoL) was a significant predictor of shorter time-to-death. Type of CTD was not associated with survival.
It is generally agreed that the MCID should be estimated using multiple methods. 15, 39, 40, 43, 44 Our estimates were different from those for IPF (7 points) . 15 This divergence may reflect differences in treatment effect between CTD-ILD and IPF. In addition, CTD-ILD encompasses a broad range of conditions, some of which behave quite differently from IPF. In our analyses, MCID was estimated using a 10% change in FVC as an anchor. In 2015, the OMERACT CTD-ILD working group proposed clinically meaningful progression for CTD-ILD as a 10% change or a 5-10% change in FVC. 42 We found that using either 5% or 10% change in FVC yielded similar results. Future prospective research may reveal the optimal FVC cut-off value as an MCID anchor.
This study has some limitations. It was a singlecentre, retrospective observational study. The numbers of patients who improved or deteriorated were relatively small, which detracts from the precision of some of the MCID estimates we generated. Additional larger prospective studies will be required to validate our results and determine the optimal MCID. We could not compare the SGRQ with other HRQoL instruments, because the SGRQ was the only questionnaire administered to our patients. Recent studies have demonstrated the clinical utility of some instruments (the Short Form-36 (SF-36), A Tool to Assess Quality of Life in IPF (ATAQ-IPF) and the King's Brief ILD Health Status Questionnaire (K-BILD)) in IPF populations. 15, 45, 46 However, they are yet to be validated in CTD-ILD. Our study is the first to demonstrate the utility of SGRQ as a HRQoL instrument in CTD-ILD. Finally, long-term (>1 year) changes in SGRQ scores could not be assessed because of short observational periods. Further follow-up studies will be needed.
In conclusion, the SGRQ appears to possess acceptable reliability, validity and responsiveness to assess HRQoL in patients with CTD-ILD. SGRQ may be an appropriate patient-reported outcome to measure HRQoL in clinical trials in patients with CTD-ILD.
